ASPE Stock Forecast: Aspen Neuroscience, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$12
+0.24% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 0 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$361.2M
Ticker Nerd rank
0/ 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−1.4%
From high
−16.6%
From low
+5.6%
$12
$15
Range since 30 Oct 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Aspen Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
0/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
20
Growth
10
Momentum
7
Value
6
Accruals
5
Quality
4
Volatility
2
Issuance
0

Revisions (20): Analysts have, on balance, been raising their forecasts.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ASPE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASPE, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ASPE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ASPE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
—
Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aspen Neuroscience, Inc. has a market value of $361.2M and an enterprise value of $637.4M.

  • Shares outstanding: 29.1M.

  • Aspen Neuroscience, Inc. employs 120 people.

market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ASPE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASPEAspen Neuroscience, Inc.$361.2M0
PBYIPuma Biotechnology, Inc.$358.8M98
PHATPhathom Pharmaceuticals, Inc.$364.9M79
RZLTRezolute, Inc.$375.1M42
ALECAlector, Inc.$346.2M94
YDESYD Bio Ltd.$342.2M3
IRDOpus Genetics, Inc.$385.7M39

Take a look at ASPE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Aspen Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ASPE

How does Ticker Nerd's model rank ASPE?

As at 21 Nov 2026, Aspen Neuroscience, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (20 of 100).

What is the ASPE stock forecast for 2030?

No analyst covering Aspen Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASPE are extrapolating price history, which says nothing about the business.

What does Aspen Neuroscience, Inc. do?

Aspen Neuroscience, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for neurodegenerative diseases. Its core platform uses a patient’s own cells to create induced pluripotent stem cells, which are differentiated into specialized neural cells intended to replace or support damaged tissue.

Company

About Aspen Neuroscience, Inc.

Aspen Neuroscience, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for neurodegenerative diseases. Its core platform uses a patient’s own cells to create induced pluripotent stem cells, which are differentiated into specialized neural cells intended to replace or support damaged tissue. The company’s leading investigational product, sasineprocel, is an autologous, single-dose cell therapy being evaluated for Parkinson’s disease. Aspen Neuroscience focuses on personalized approaches that may help address neurological conditions involving the loss or dysfunction of specific cell types. Its activities span cell biology, stem-cell manufacturing, translational research, and clinical development, positioning the company within the regenerative medicine and advanced therapies sectors. Headquartered in San Diego, California, Aspen Neuroscience serves the biotechnology and healthcare markets by developing patient-specific treatments for disorders with substantial unmet medical needs. Its work reflects the growing role of autologous cell-based platforms in precision medicine and neurological disease research.

CEO Dr. Damien McDevitt Ph.D. · 120 employees · United States · https://www.aspenneuroscience.com